HUTCHMED (China) Limited (AIM:HCM)
212.00
+5.00 (2.42%)
Apr 17, 2025, 4:35 PM GMT+1
HUTCHMED (China) Revenue
In the year 2024, HUTCHMED (China) had annual revenue of $630.20M USD, down -24.80%. HUTCHMED (China) had revenue of $324.52M in the half year ending December 31, 2024, with 44.64% growth.
Revenue
$630.20M
Revenue Growth
-24.80%
P/S Ratio
3.60
Revenue / Employee
$347.99K
Employees
1,811
Market Cap
1.81B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
Oxford Nanopore Technologies | 183.19M |
Genus | 671.60M |
HUTCHMED (China) News
- 4 days ago - Hutchmed weighs cancer drug’s supply-chain options amid US-China trade war - South China Morning Post
- 4 weeks ago - HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma - GlobeNewsWire
- 4 weeks ago - Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewsWire
- 4 weeks ago - US pharma restrictions won't affect Hutchmed operations, says CEO - CNBC
- 4 weeks ago - HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewsWire
- 4 weeks ago - Hutchmed spikes after cancer trial win despite 2024 revenue miss - Seeking Alpha
- 4 weeks ago - HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength - Benzinga